HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators will evaluate the use of an HLA-DQ2-gliadin tetramer for staining of gluten specific T cells in the diagnostics of uncertain celiac disease. Some patients have started on a gluten free diet without a diagnosis of celiac disease. Subsequent later investigation in special care is difficult as the patients often are reluctant to prolonged gluten challenge. The investigators use the HLA-DQ2-gliadin tetramers for detection of gluten specific T cells after a short gluten challenge. By this method the investigators search to discriminate between true celiac disease and clinical gluten intolerance without celiac disease, in a population of HLA-DQ2+ persons already on a gluten free diet without a formal diagnosis of celiac disease.
| Condition | Intervention | Phase |
|---|---|---|
|
Celiac Disease Gluten |
Dietary Supplement: Gluten challenge. |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
- HLA-DQ2-tetramer response after gluten challenge [ Time Frame: 6 days. ] [ Designated as safety issue: No ]FACS analysis of peripheral blood after gluten challenge.
- Mucosal responses to 3 day gluten challenge. [ Time Frame: 4 days. ] [ Designated as safety issue: No ]Biopsy the fourth day of gluten challenge.
| Enrollment: | 100 |
| Study Start Date: | September 2006 |
| Study Completion Date: | September 2012 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Gluten challenge.
Diagnosis of celiac disease. Before and after a gluten challenge small bowel biopsies will be taken, and blood samples will be drawn for tetramer staining of gluten specific T cells.
|
Dietary Supplement: Gluten challenge.
The study population consists of 50 HLA-DQ2+ patients on a gluten free diet, both celiacs and uncertain celiacs. The patients will undergo a oral gluten challenge with four slices of bread daily for three days. Before challenge blood samples will be drawn for tetramer staining of gluten-specific T-cells. The analysis is done at the Institute of Immunology at Rikshospitalet, using FACS analysis. Small intestinal biopsies will be examined for morhological changes and inflammatory gene expression. These procedures with blood samples and biopsies will be repeated after gluten challenge. Registration for clinical symptoms and personality traits will be done by standardised and validated forms. A dietist will perform an interview of the patients.
|
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- HLA-DQ2+ celiacs and HLA-DQ2+ persons who have been on a gluten free diet for at least 4 weeks.
Exclusion Criteria:Pregnancy
- Other severe disease
- Refusal to participate
- HLA-DQ2 negativity
Contacts and Locations
More Information
Publications:
| Responsible Party: | Oslo University Hospital |
| ClinicalTrials.gov Identifier: | NCT01100099 History of Changes |
| Other Study ID Numbers: | 2007068, 2007068 2009021 |
| Study First Received: | April 6, 2010 |
| Last Updated: | September 18, 2012 |
| Health Authority: | Norway: Ministry of Health and Care Services |
Keywords provided by Oslo University Hospital:
|
Celiac disease. Food intolerance. Gluten intolerance without celiac disease. |
Additional relevant MeSH terms:
|
Celiac Disease Malabsorption Syndromes Intestinal Diseases |
Gastrointestinal Diseases Digestive System Diseases Metabolic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013